2.04
1.53%
0.0307
アフターアワーズ:
2.01
-0.03
-1.47%
前日終値:
$2.0093
開ける:
$2.01
24時間の取引高:
6,509
Relative Volume:
0.34
時価総額:
$3.27M
収益:
-
当期純損益:
$-36.46M
株価収益率:
-12.75
EPS:
-0.16
ネットキャッシュフロー:
$-30.20M
1週間 パフォーマンス:
-1.45%
1か月 パフォーマンス:
-22.43%
6か月 パフォーマンス:
-84.31%
1年 パフォーマンス:
-82.18%
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-10-04 | 再開されました | Wells Fargo | Overweight |
Alaunos Therapeutics Inc (TCRT) 最新ニュース
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
An Analysis of Atricure Inc (ATRC)’s Potential Price Growth - Knox Daily
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Applied Therapeutics jumps as US FDA cancels panel meeting for genetic disorder drug - XM
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Daily Market Movement: Atricure Inc (ATRC) Sees a -3.23 Decrease, Closing at 27.30 - The Dwinnex
Aptevo Therapeutics announces $3.0M offering priced at-the-market - TipRanks
Check out these key findings about Atricure Inc (ATRC) - SETE News
Atmos Energy Co. (NYSE:ATO) Shares Sold by Prudential PLC - MarketBeat
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Ziopharm: Q2 Earnings Snapshot - San Antonio Express-News
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 4.2% - Defense World
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
TCRT stock touches 52-week low at $3.57 amid market challenges - Investing.com Nigeria
Alaunos Therapeutics announces 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Intracranial Therapeutic Industry Startegy Analysis} Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics ... - Economica
Alaunos (TCRT) Dips More Than Broader Markets: What You Should Know - Yahoo New Zealand News
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings ... - Yahoo Lifestyle UK
Alaunos Therapeutics appoints new accounting firmInvesting.com ZA - Investing.com South Africa
Alaunos Therapeutics appoints new accounting firm By Investing.com - Investing.com
Ziopharm Oncology to Participate in Upcoming Conferences - Quantisnow
Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25 ... - Quantisnow
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations - Quantisnow
New Strong Buy Stocks for November 18th - Yahoo Movies Canada
Commerce Bank Decreases Stock Position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) - Defense World
The past five years for Alaunos Therapeutics (NASDAQ:TCRT) investors has not been profitable - Yahoo News Australia
Quarterly Metrics: Quick and Current Ratios for Alaunos Therapeutics Inc (TCRT) – DWinneX - The Dwinnex
Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology
Alaunos Therapeutics Reports First Quarter 2023 Financial Results - br.ADVFN.com
AltruBio secures $225m for immune checkpoint programme development - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 3.6% - Defense World
Alaunos Therapeutics (NASDAQ:TCRT) investors are sitting on a loss of 78% if they invested three years ago - Yahoo Lifestyle UK
Ziopharm: Q1 Earnings Snapshot - Milford Mirror
Alaunos (TCRT) Stock Sinks As Market Gains: What You Should Know - Yahoo Lifestyle Australia
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Alaunos Therapeutics Inc (TCRT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):